From the American Heart Journal: Analysis of 15,259 AMI #cardiogenicshock U.S. patients in the #Impella Quality Database demonstrated an improvement in survival to explant from 52% to 59% when #Impella was placed pre-PCI (p=0.001) bit.ly/2YM2INc

From Abiomed's Twitter

A @CircRes analysis reinforces best practices of reduced use of inotropes and placement of #Impella pre-PCI leads to improved survival rates. Survival benefit of Impella pre-PCI revealed trend vs “matched” IABP-Shock: 57.3% vs. 46.7% (p=0.18) bit.ly/2YOZKaN

From Abiomed's Twitter

Data from the first 104 patients utilizing best practices in the #NationalCSI Cardiogenic Shock Initiative (NCSI) Study found 77% survival to discharge with 99% native #heartrecovery bit.ly/2NeHUac

From Abiomed's Twitter